Michael Grever is a Hematology physician affiliated with The Ohio State University Wexner Medical Center. OpenAlex indexes 547 publications with 39,500 citations (h-index 78); ClinicalTrials.gov lists 2 registered studies matched to this name. By OpenAlex citation count, this profile ranks in the top 5% of Hematology profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
460 W 10th Ave
Columbus, OH 432101240
Telephone
614-293-3196Provider last certified this registry record 26 Feb 2026.
Clinical trials
- Hairy Cell Leukemia Patient Data Registry
Sponsor: Ohio State University Comprehensive Cancer Center
- Temsirolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma
Sponsor: National Cancer Institute (NCI)
- Fludarabine With or Without Cyclophosphamide in Treating Patients With Chronic Lymphocytic Leukemia
Sponsor: Eastern Cooperative Oncology Group
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Deciphera Pharmaceuticals Inc.Program year20231 payment
- EMD Serono, Inc.Program year20221 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2021)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
100%Kinase inhibitor100%Imbruvica100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
13 NIH research awards on record, funded 1985–2017 per NIH RePORTER. The latest:
- Experimental Therapeutics of Anti-Cancer Agents with Phase I Emphasis
Ohio State University
FY2017$300,000UM1CA186712 - Experimental Therapeutics of Anti-Cancer Agents with Phase I Emphasis
Ohio State University
FY2016$957,122UM1CA186712 - UM1 Supplement for Early Therapeutic Trials with Phase 2 Intent
Ohio State University
FY2016$861,323UM1CA186712
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Timothy Pawlik, MD
The Ohio State University Wexner Medical Center
Colleen Cebulla, MD
The Ohio State University Wexner Medical Center
Brad Rovin, MD
The Ohio State University Wexner Medical Center
Matthew Ringel, MD
The Ohio State University Wexner Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”